Search Results - "Watanabe, Jonathan"

Enhancing drug evaluation in diverse populations and older adults: National Academies of Sciences, Engineering, and Medicine considerations by Watanabe, Jonathan H.

Get full text

Cost of Prescription Drug–Related Morbidity and Mortality by Watanabe, Jonathan H., McInnis, Terry, Hirsch, Jan D.

“…Background: Public attention and recent US Congressional activity has intensified focus on escalating medication prices. However, the actual cost of medication…”
Get full text

Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022 by Watanabe, Jonathan H., Kwon, Jimmy, Nan, Bin, Reikes, Andrew

“…Recent Food and Drug Administration approvals of glucagon-like peptide 1 (GLP-1) receptor agonists linked to substantial weight loss have generated interest in…”
Get full text

Emergency Department Visits for Psychotropic-Related Adverse Drug Events in Older Adults With Alzheimer Disease, 2013-2014 by Sepassi, Aryana, Watanabe, Jonathan H.

“…Background: More than 1.3 million emergency department visits have been associated with adverse drug events (ADEs) in older adults. Increasing Alzheimer’s…”
Get full text

Improving Care for Opioid Use Disorder in Nursing Facilities by Watanabe, Jonathan H

Get more information

Pharmacist-directed care to optimize medication use: a healthcare imperative in the United States by Watanabe, Jonathan H

Get more information

The Critical Role of Pharmacists in Treating Older People in the Opioid Crisis by Watanabe, Jonathan H

“…Pharmacy-based Opioid Use Disorder (OUD) treatment has been identified as a central pillar in curbing the spiraling opioid epidemic that claimed more than…”
Get more information

Association of Age and Hospitalization Amongst Those with Underlying High-risk Conditions at COVID-19 Diagnosis in a Large, State-wide Health System by Watanabe, Jonathan H., Kwon, Jimmy, Mehta, Sanjay R.

Get full text

Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population by Kazerooni, Rashid, Watanabe, Jonathan H

“…The Centers for Medicare & Medicaid Services (CMS) is the single largest payer for health care in the United States and the largest payer by spending globally…”
Get full text

Aspirin Use in Older People Highlights the Need for Improved Inclusion of Older People in Clinical Trials by Watanabe, Jonathan H, Zajac, Dagmara

Get more information

Association of Pre-Pandemic Telehealth With Emergency Department and Telehealth Usage During the Pandemic by Strand, Michael, Watanabe, Jonathan H

“…Aims were to quantify the association of pre-COVID-19 pandemic telehealth use and separately: 1) likelihood of an emergency department (ED) visit, 2)…”
Get more information

An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013 by Bounthavong, Mark, Li, Meng, Watanabe, Jonathan H.

“…Previous estimates of the economic burden of Crohn's disease (CD) varied widely from $2.0 to $18.2 billion per year (adjusted to 2015 $US). However, these…”
Get full text

Revisiting the medication possession ratio threshold for adherence in lipid management by Watanabe, Jonathan H., Bounthavong, Mark, Chen, Timothy

“…Abstract Objective: We sought to evaluate the relationship between different levels of medication possession ratio (MPR) attained and achievement of clinically…”
Get full text

When Can We Trust Real‐World Data To Evaluate New Medical Treatments? by Simon, Gregory E., Bindman, Andrew B., Dreyer, Nancy A., Platt, Richard, Watanabe, Jonathan H., Horberg, Michael, Hernandez, Adrian, Califf, Robert M.

“…Concerns regarding both the limited generalizability and the slow pace of traditional randomized trials have led to calls for greater use of real‐world…”
Get full text

Hospitalization and Combined Use of Opioids, Benzodiazepines, and Muscle Relaxants in the United States by Watanabe, Jonathan H., Yang, Jincheng

“…Introduction: Concurrent opioid and benzodiazepine use (“double-threat”) and double-threat and muscle relaxant use (“triple-threat”) are postulated to increase…”
Get full text

When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments? by Franklin, Jessica M., Platt, Richard, Dreyer, Nancy A., London, Alex John, Simon, Gregory E., Watanabe, Jonathan H., Horberg, Michael, Hernandez, Adrian, Califf, Robert M.

“…The randomized controlled trial (RCT) is the gold standard for evaluating the causal effects of medications. Limitations of RCTs have led to increasing…”
Get full text

Exploring Concomitant Acetylcholinesterase Inhibitor and Overactive Bladder Anticholinergic Use and Risk of Hospitalization in Medicare and Dual-Eligible Medicare–Medicaid Populations in a Historic Database by Watanabe, Jonathan H, Hoang, Tu

“…Overactive bladder prevalence increases in older adults often complicating the management of other comorbidities. The theoretical antagonism between the…”
Get full text

When Are Treatment Blinding and Treatment Standardization Necessary in Real‐World Clinical Trials? by Watanabe, Jonathan H, Simon, Gregory E, Horberg, Michael, Platt, Richard, Hernandez, Adrian, Califf, Robert M

“…Concerns regarding both the limited generalizability and the slow pace of traditional randomized trials have led to calls for greater use of real‐world…”
Get full text

Minding the gap and the value of metrics: Count of working pharmacists in the United States by Hirsch, Jan D., Nguyen, Megan H., Abugazia, Jamilla, Watanabe, Jonathan H.

“…The Bureau of Labor Statistics (BLS) uses a single Standard Occupational Classification (SOC) code (29-1051) that reflects a traditional definition of…”
Get full text

Examining the Impact of the World Health Organization 2022 Guidelines on Evaluation of Biosimilars for Non-Local Comparators in Biosimilar Studies on Middle East and North Africa Member States by Strand, Michael W, Watanabe, Jonathan H

“…Global support and standardization of regulation for biosimilars approval owes much of its legacy to the World Health Organization (WHO), since the first…”
Get full text